SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
18520803
Source:
http://linkedlifedata.com/resource/pubmed/id/18520803
Search
Subject
(
58
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0007131
,
umls-concept:C0030705
,
umls-concept:C0205179
,
umls-concept:C0282460
,
umls-concept:C1134654
pubmed:issue
6
pubmed:dateCreated
2008-6-3
pubmed:abstractText
To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC).
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/101274235
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/ABT751
,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1556-1380
pubmed:author
pubmed-author:CoatesAndrew IAI
,
pubmed-author:CohenEzra E WEE
,
pubmed-author:GordonGary BGB
,
pubmed-author:HageyAnne EAE
,
pubmed-author:KozloffMark FMF
,
pubmed-author:MaPatrick CPC
,
pubmed-author:MauerAnn MAM
,
pubmed-author:QianJiangJ
,
pubmed-author:SchwartzbergLeeL
pubmed:issnType
Electronic
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
631-6
pubmed:meshHeading
pubmed-meshheading:18520803-Adult
,
pubmed-meshheading:18520803-Aged
,
pubmed-meshheading:18520803-Aged, 80 and over
,
pubmed-meshheading:18520803-Carcinoma, Non-Small-Cell Lung
,
pubmed-meshheading:18520803-Disease Progression
,
pubmed-meshheading:18520803-Disease-Free Survival
,
pubmed-meshheading:18520803-Dose-Response Relationship, Drug
,
pubmed-meshheading:18520803-Female
,
pubmed-meshheading:18520803-Humans
,
pubmed-meshheading:18520803-Lung Neoplasms
,
pubmed-meshheading:18520803-Male
,
pubmed-meshheading:18520803-Middle Aged
,
pubmed-meshheading:18520803-Neoplasm Staging
,
pubmed-meshheading:18520803-Questionnaires
,
pubmed-meshheading:18520803-Severity of Illness Index
,
pubmed-meshheading:18520803-Sulfonamides
,
pubmed-meshheading:18520803-Survival Rate
,
pubmed-meshheading:18520803-Treatment Outcome
,
pubmed-meshheading:18520803-United States
pubmed:year
2008
pubmed:articleTitle
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
pubmed:affiliation
University of Chicago Medical Center, Chicago, Illinois 60637, USA. ann.mauer-md@advocatehealth.com
pubmed:publicationType
Journal Article
,
Comparative Study
,
Randomized Controlled Trial
,
Multicenter Study
,
Clinical Trial, Phase II